1-[4-[5-(4-Fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-3-hydroxyurea

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[4-[5-(4-Fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-3-hydroxyurea
• 化学式: C₁₅H₁₃FN₂O₄
• 分子量: 304.27
• InChiKey: HBRAAJXVMNFKFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  83.7
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS<br/>[FR] COMBINAISONS A EFFETS IMMUNODEPRESSEURS RENFERMANT DES INHIBITEURS DE CYCLOOXYGENASE-2 ET DE 5-LIPOOXYGENASE
  申请人：G.D. SEARLE & CO.

  公开号：WO1997029776A1

  公开（公告）日：1997-08-21

  (EN) Treatment with a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases.(FR) Traitement par inhibiteur de cyclooxygénase-2 et de 5-lipooxygénase tendant à réduire le risque de rejet par le receveur d'organes transplantés. Ce traitement vise également les maladies autoimmunes.

  (中) 通过使用环氧化酶-2抑制剂和5-脂氧合酶抑制剂的治疗被描述为有助于减少移植器官接受者的排斥反应，并用于治疗自身免疫性疾病。
• Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
  申请人：G.D. Searle & Co.

  公开号：US20020143033A1

  公开（公告）日：2002-10-03

  This invention is in the field of a combination comprising a therapeutically-effective amount of a cyclooxygenase-2 inhibitor, a 5-lipoxygenase inhibitor and an immunosuppressive drug selected from antiproliferative agents, antiinflammatory-acting compounds and inhibitors of leukocyte activation. This combination may be used, for example, to suppress the immune response associated with organ transplantation, graft versus host disease, and conditions with underlying autoimmune or inflammatory reactivities or responses.

  本发明涉及一种组合物，包括治疗有效量的环氧合酶-2抑制剂、5-脂氧合酶抑制剂和免疫抑制药物，所述免疫抑制药物选自抗增殖剂、抗炎症作用化合物和白细胞激活抑制剂。该组合物可用于抑制与器官移植、移植物抗宿主病和基于自身免疫或炎症反应的疾病相关的免疫反应。
• Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway
  申请人：O'Connor James Patrick

  公开号：US20110105959A1

  公开（公告）日：2011-05-05

  Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods rely on in vivo or ex vivo modulation of an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors, leukotriene A4 hydrolase inhibitors, and/or leukotriene B4 receptor antagonists. These molecules can be delivered alone or in combination with one or more agents that inhibit bone resorption, regulate calcium resorption from bone, enhance bone accumulation, enhance bone formation, induce bone formation, impair growth of microorganisms, reduce inflammation, and/or reduce pain.

  公开了促进成骨作用以加速或增强骨折愈合、治疗骨缺陷和增强骨形成的方法。这些方法依赖于体内或体外调节花生四烯酸代谢或信号通路的总体，特别是利用5-脂氧合酶抑制剂、白三烯A4水解酶抑制剂和/或白三烯B4受体拮抗剂。这些分子可以单独或与一个或多个抑制骨吸收、调节从骨中钙吸收、增强骨积累、增强骨形成、诱导骨形成、抑制微生物生长、减少炎症和/或减轻疼痛的剂量联合使用。
• COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR
  申请人：G.D. SEARLE & CO.

  公开号：EP0833622B1

  公开（公告）日：2005-08-10
• COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS
  申请人：G.D. SEARLE & CO.

  公开号：EP0888127A1

  公开（公告）日：1999-01-07